BIOLASE Inc. [NASDAQ: BIOL] plunged by -$0.01 during the normal trading session on Thursday and reaching a high of $0.85 during the day while it closed the day at $0.83. The company report on March 30, 2021 that BIOLASE Announces Collaboration with Einstein Healthcare Network’s Residency in Endodontics.
Endodontic residents receive hands-on training with dental lasers to further education and foster easy integration into future dental practices.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced a pilot program with Einstein Healthcare Network’s residency in endodontics to train endodontic residents in the use of Waterlase dental lasers. The goal of the program is to offer residents hands-on experience with dental lasers that are already in use across the industry, allowing residents to immediately implement their training when joining a future practice.
BIOLASE Inc. stock has also loss -13.42% of its value over the past 7 days. However, BIOL stock has inclined by 76.81% in the 3 months of the year. Over the past six months meanwhile, it has gained 202.07% and gained 99.42% year-on date.
The market cap for BIOL stock reached $123.00 million, with 145.98 million shares outstanding and 91.52 million shares in the current float. Compared to the average trading volume of 31.18M shares, BIOL reached a trading volume of 3918231 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BIOLASE Inc. [BIOL]:
The Benchmark Company have made an estimate for BIOLASE Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on June 19, 2019. While these analysts kept the previous recommendation, Singular Research raised their target price to Buy. The new note on the price target was released on April 25, 2017, representing the official price target for BIOLASE Inc. stock. Previously, the target price had yet another drop from $4 to $2.50, while WallachBeth kept a Hold rating on BIOL stock. On November 12, 2013, analysts decreased their price target for BIOL shares from 3.50 to 2.75.
The Average True Range (ATR) for BIOLASE Inc. is set at 0.09, with the Price to Sales ratio for BIOL stock in the period of the last 12 months amounting to 5.39. The Price to Book ratio for the last quarter was 4.89, with the Price to Cash per share for the same quarter was set at 0.13.
BIOL stock trade performance evaluation
BIOLASE Inc. [BIOL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.42. With this latest performance, BIOL shares dropped by -4.94% in over the last four-week period, additionally plugging by 202.07% over the last 6 months – not to mention a rise of 232.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOL stock in for the last two-week period is set at 40.58, with the RSI for the last a single of trading hit 35.25, and the three-weeks RSI is set at 44.37 for BIOLASE Inc. [BIOL]. The present Moving Average for the last 50 days of trading for this stock 1.0421, while it was recorded at 0.8452 for the last single week of trading, and 0.5463 for the last 200 days.
BIOLASE Inc. [BIOL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BIOLASE Inc. [BIOL] shares currently have an operating margin of -81.37 and a Gross Margin at +27.10. BIOLASE Inc.’s Net Margin is presently recorded at -73.88.
Return on Total Capital for BIOL is now -80.38, given the latest momentum, and Return on Invested Capital for the company is -104.10. Return on Equity for this stock declined to -234.22, with Return on Assets sitting at -45.61. When it comes to the capital structure of this company, BIOLASE Inc. [BIOL] has a Total Debt to Total Equity ratio set at 179.10. Additionally, BIOL Total Debt to Total Capital is recorded at 64.17, with Total Debt to Total Assets ending up at 43.78. Long-Term Debt to Equity for the company is recorded at 181.23, with the Long-Term Debt to Total Capital now at 64.17.
Receivables Turnover for the company is 3.85 with a Total Asset Turnover recorded at a value of 0.62.BIOLASE Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.70.
Earnings per share (EPS) analysis for BIOLASE Inc. [BIOL] stock
With the latest financial reports released by the company, BIOLASE Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIOL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BIOLASE Inc. go to 20.00%.
BIOLASE Inc. [BIOL]: Insider Ownership positions
There are presently around $6 million, or 11.70% of BIOL stock, in the hands of institutional investors. The top three institutional holders of BIOL stocks are: ORACLE INVESTMENT MANAGEMENT INC with ownership of 1,739,100, which is approximately 0% of the company’s market cap and around 5.26% of the total institutional ownership; VANGUARD GROUP INC, holding 1,287,859 shares of the stock with an approximate value of $1.07 million in BIOL stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $1.01 million in BIOL stock with ownership of nearly 9.473% of the company’s market capitalization.
Positions in BIOLASE Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 22 institutional holders increased their position in BIOLASE Inc. [NASDAQ:BIOL] by around 2,994,185 shares. Additionally, 15 investors decreased positions by around 754,598 shares, while 8 investors held positions by with 3,654,932 shares. The mentioned changes placed institutional holdings at 7,403,715 shares, according to the latest SEC report filing. BIOL stock had 12 new institutional investments in for a total of 1,252,523 shares, while 10 institutional investors sold positions of 309,320 shares during the same period.